• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed

    3/1/21 8:21:02 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CBPO alert in real time by email
    6-K 1 tm218258d1_6k.htm FORM 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2021

     

    Commission File Number 001-34566

     

     

    China Biologic Products Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    18th Floor, Jialong International Building, 19 Chaoyang Park Road

    Chaoyang District, Beijing 100125

    People’s Republic of China

    (+86) 10-6598-3111

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ 

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ 

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
    Date: March 1, 2021   By: /s/ Joseph Chow
            Name: Joseph Chow
            Title: Chairman of the Board of Directors

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit Number 

     

    Description 

    99.1   Press release dated March 1, 2021 titled “China Biologic Announces Shareholders’ Approval of Merger Agreement”

     

     

     

     

    Get the next $CBPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CBPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    China Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ "Deal of the Year - Large Cap"

    HONG KONG, Nov. 16, 2021 /PRNewswire/ -- The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. ("China Biologic" or the "Company") was awarded "Deal of the Year – Large Cap" by Asia Venture Capital Journal (AVCJ) at its annual award ceremony on November 15 in Hong Kong. A buyer consortium led by Centurium Capital first announced its indicative proposal to privatize the Nasdaq-listed China Biologic (NASDAQ:CBPO) on September 18, 2019. On November 19, 2020, the two sides had reached an agreement for the consortium to purchase the outstanding shares not already owned by the consortium members at US$120 per share, implying

    11/16/21 10:11:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    China Biologic Announces Completion of Going Private Transaction

    BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ:CBPO, ", China Biologic", or the ", Company", ))), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger Sub"), a wholly owned subsidiary of CBPO Holdings Limited ("Parent"), pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement") among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company. Pursuant to the terms of the

    4/20/21 4:30:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

    BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019. Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019. Income from operations increased

    3/29/21 4:30:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBPO
    SEC Filings

    View All

    SEC Form 15-12B filed by China Biologic Products Holdings, Inc.

    15-12B - China Biologic Products Holdings, Inc. (0001369868) (Filer)

    4/30/21 6:13:29 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by China Biologic Products Holdings, Inc.

    S-8 POS - China Biologic Products Holdings, Inc. (0001369868) (Filer)

    4/21/21 8:52:06 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by China Biologic Products Holdings, Inc.

    S-8 POS - China Biologic Products Holdings, Inc. (0001369868) (Filer)

    4/21/21 8:50:57 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBPO
    Financials

    Live finance-specific insights

    View All

    China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

    BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019. Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019. Income from operations increased

    3/29/21 4:30:00 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

    4/22/21 4:23:32 PM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

    4/22/21 9:15:17 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by China Biologic Products Holdings, Inc. (Amendment)

    SC 13D/A - China Biologic Products Holdings, Inc. (0001369868) (Subject)

    4/22/21 9:10:09 AM ET
    $CBPO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care